HK Stock Market Move | SUN.KING TECH (00580) rose more than 7% in early trading, signing a 1.43 billion yuan offshore wind power project power electronic device agreement.
Sage Technology (00580) rose more than 7% in early trading, as of the time of publication, it was up 3.59% to HK$2.02, with a turnover of HK$2.8446 million.
SUN.KING TECH (00580) rose by more than 7% in the morning session, as of the time of writing, it has increased by 3.59% to HKD 2.02, with a trading volume of HKD 2.8446 million.
On the news front, SUN.KING TECH announced that its subsidiary has signed an agreement with a subsidiary of Nanjing NARI. According to the agreement, Nanjing NARI will purchase power electronic devices with a total amount of RMB 143 million, and the company will deliver them in batches in the first half of 2026. These power electronic devices will be used in offshore wind power projects.
Zhongtai International previously pointed out that during the "14th Five-Year Plan" period, ultra-high voltage projects will mainly focus on flexible power transmission technology. SAI Crystal is a leading domestic supplier of transmission and distribution electrical components, with sufficient orders on hand and steadily increasing related income; the increase in the localization rate of transmission and distribution electrical components is beneficial to support gross profit margin; at the same time, benefiting from the increase in the penetration of domestic power semiconductor devices, self-developed IGBT chip business income has grown explosively.
Related Articles

CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.






